These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1794261)

  • 21. Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin.
    Serradas P; Bailbé D; Portha B
    Diabetologia; 1989 Aug; 32(8):577-84. PubMed ID: 2528491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial.
    Shaw KM; Wheeley MS; Campbell DB; Ward JD
    Diabet Med; 1985 Nov; 2(6):484-90. PubMed ID: 2951123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of gliclazide in the treatment of non-insulin-dependent diabetes mellitus: a Canadian multicenter study.
    Mailhot J
    Clin Ther; 1993; 15(6):1060-8. PubMed ID: 8111803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gliclazide and insulin action in human muscle.
    Bak JF; Pedersen O
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S61-4. PubMed ID: 1794267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
    Vestergaard H; Lund S; Bjørbaek C; Pedersen O
    Diabetologia; 1995 Oct; 38(10):1230-8. PubMed ID: 8690177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.
    McAlpine LG; McAlpine CH; Waclawski ER; Storer AM; Kay JW; Frier BM
    Eur J Clin Pharmacol; 1988; 34(2):129-32. PubMed ID: 3289948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects.
    Ward G; Harrison LC; Proietto J; Aitken P; Nankervis A
    Diabetes; 1985 Mar; 34(3):241-5. PubMed ID: 3882491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of sulfonylurea agents on pyruvate dehydrogenase activity in circulating lymphocytes from patients with non-insulin-dependent diabetes mellitus (NIDDM).
    Rinaudo MT; Curto M; Rabbone I; Piccinini M; Bruno R; Mioletti S; Gamba S
    J Diabetes Complications; 1994; 8(4):221-5. PubMed ID: 7833497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
    Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Personal experience with combined treatment of gliclazide and insulin in patients with non-insulin-dependent diabetes (type 2) and late secondary failure of sulphonylureas].
    Zapecka-Dubno B; Wiśniewska K; Szczepanik Z; Kasperska-Czyzykowa T
    Pol Arch Med Wewn; 1993 Jun; 89(6):499-506. PubMed ID: 8415212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The management of non-insulin-dependent diabetes mellitus in the elderly.
    Ruoff G
    J Fam Pract; 1993 Mar; 36(3):329-35. PubMed ID: 8454981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
    Colagiuri S; Matthews D; Leiter LA; Chan SP; Sesti G; Marre M
    Diabetes Res Clin Pract; 2018 Sep; 143():1-14. PubMed ID: 29802958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Metabolic effects of gliclazide in diabetes type II patients. Study with indirect calorimetry].
    Golay A; Broquet C; Chabot V; Studer S; Felber JP
    Schweiz Med Wochenschr; 1984 Feb; 114(8):261-4. PubMed ID: 6369531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment.
    Desfaits AC; Serri O; Renier G
    Diabetes Care; 1998 Apr; 21(4):487-93. PubMed ID: 9571329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Langtry HD; Balfour JA
    Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
    Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
    Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of long term gliclazide administration on insulin secretion and insulin sensitivity.
    Ma A; Kamp M; Bird D; Howlett V; Cameron DP
    Aust N Z J Med; 1989 Feb; 19(1):44-9. PubMed ID: 2669710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide.
    Akanuma Y; Kosaka K; Kanazawa Y; Kasuga M; Fukuda M; Aoki S
    Am J Med; 1991 Jun; 90(6A):74S-76S. PubMed ID: 1872308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemobiological properties of gliclazide.
    Ziegler O; Drouin P
    J Diabetes Complications; 1994; 8(4):235-9. PubMed ID: 7833500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of NIDDM with insulin agonists or substitutes.
    Galloway JA
    Diabetes Care; 1990 Dec; 13(12):1209-39. PubMed ID: 1980453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.